以色列總理內塔尼亞胡：我們在約旦河西岸、加沙和黎巴嫩打擊恐怖主義的行動將持續全力進行。

September 4 — Merck said China’s NMPA approved its PD‑1 inhibitor pembrolizumab for adults with resectable locally advanced head‑and‑neck squamous cell carcinoma whose tumors express PD‑L1 (combined positive score CPS ≥1) by a validated test. Approval covers single‑agent neoadjuvant use, postoperative adjuvant radiotherapy with or without cisplatin, and continued pembrolizumab monotherapy thereafter.

Anthropic：多個模型已恢復至基準水平。